Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Selectively and dose-dependently inhibits COX-2 within the clinical dose range, reducing prostaglandin synthesis associated with pain and inflammation; it does not inhibit COX-1 at doses up to 150 mg daily in cited clinical pharmacology studies.
Indications / reported uses
Symptomatic relief of osteoarthritis and rheumatoid arthritis
Ankylosing spondylitis
Pain and signs of inflammation associated with acute gouty arthritis
Short-term treatment of moderate pain associated with dental surgery; age and dose restrictions are product-specific
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Etoricoxib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Etoricoxib Permitted Daily Exposure (PDE) report (the Etoricoxib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Etoricoxib Occupational Exposure Limit (OEL) report (the Etoricoxib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.